The Nordic Health Summit Japan 2023 kicks off at the Embassy of Sweden in Tokyo, but can also be followed online. For online participation, please register through Zoom.
We are honored to announce that Eisai will be joining us to talk about their collaboration with Sweden’s BioArctic that lead to highly publicized, FDA approved Alzheimer’s drug “Lecanemab,” developed through a partnership between Eisai and Biogen.
Ambassador of Finland to Japan, Tanja Katriina Jääskeläinen
Opening Remarks
Introducing the Nordics
Charlotte af Klercker Business Sweden
Keynote Speech
Hiroyuki Kato, Ph.D.
Hiroyuki Kato joined Eisai Co., Ltd. in R&D. He has been in charge of development research, quality, etc. as VP since 2016, and since 2019, he has been Chief Clinical Quality Officer, Chief Product Quality Officer, in charge of Global Product Emergency Management and in charge of Regulatory Affairs as SVP. He became a member of the Board in June 2022. He was responsible for collaboration with BioArctic in Sweden as part of focus on collaboration with external parties in discovery research.
14:25
Japanese experience of healthcare investing in and collaboration with the Nordic
Peter Takizawa, ALK Commercial Liaison Director Peter is born and raised in Sweden, came to Japan in 2001 and has worked in the Japanese life science industry for over twenty years with roles in S&M and consulting. Before starting up the ALK liaison office earlier in the year, Peter was senior commercial advisor of life science at the Royal Danish Embassy in Tokyo.
Atsuyuki Kakee, Ph.D. Torii Pharmaceutical Co.Ltd. Head of Innovation Group Graduate School of Pharmaceutical Sciences in Kyoto University. After joining Japan Tobacco, had been engaged in pharmaceutical research and development, and was appointed Vice President of Clinical Research Planning Department in 2006, Vice President of Clinical Development Department in 2012. In 2015, transferred to Torii Pharmaceutical and is currently Senior Executive Officer, Head of Innovation Group.
Lei Liu, Ph.D., AstraZeneca K.K. Innovation Partnerships & i2.JP Director After working for a foreign medical device company in R&D, a domestic think tank/consulting firm, a foreign life insurance company, and a start-up, joined AZKK in January 2020. In charge of open innovation promotion and leading the launching of i2.JP, an open innovation network, in November 2020. Planning and promoting collaborative projects in i2.JP community involving public, private, academic partners and start-ups with the aim to achieve patient-centricity.
Yoshihiro Arai, Solasia Pharma K.K. President & Chief Executive Officer Yoshi participated in the launch of Solasia Pharma K.K. in 2007 as Executive Vice President of the Development Division, and has been President & Chief Executive Officer since 2013. Prior to joining Solasia Pharma KK., Yoshi spent 14 years at Amgen KK as director of Clinical Development Operation/Project Management & Strategic Operations. Yoshi graduated Tokyo University of Pharmacy & Life Sciences (Pharmacist license), and earned a B.S degree and a Master degree in Biochemistry & Microbiology from the University and a M.B.A. from the University of Wales.
